FY2028 Earnings Estimate for Scholar Rock Issued By Wedbush

Scholar Rock Holding Co. (NASDAQ:SRRK) – Analysts at Wedbush raised their FY2028 earnings estimates for Scholar Rock in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.39 per share for the year, up from their previous forecast of $0.33. Wedbush currently has a “Outperform” rating and a $37.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.37) per share.

Other analysts have also issued reports about the stock. JPMorgan Chase & Co. upped their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, October 14th. HC Wainwright increased their price target on shares of Scholar Rock from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. BMO Capital Markets lifted their target price on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, October 11th. Finally, Piper Sandler increased their price objective on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Scholar Rock has an average rating of “Buy” and a consensus price target of $34.00.

Scholar Rock Stock Up 0.3 %

SRRK traded up $0.07 on Thursday, hitting $27.45. 19,083 shares of the company were exchanged, compared to its average volume of 1,130,480. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.36. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -11.65 and a beta of 0.47. The firm has a 50-day moving average price of $19.86 and a two-hundred day moving average price of $13.43. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $35.38.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 30,000 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $25.62, for a total transaction of $768,600.00. Following the transaction, the insider now directly owns 49,285 shares in the company, valued at approximately $1,262,681.70. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Tracey Sacco sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $25.62, for a total transaction of $768,600.00. Following the completion of the transaction, the insider now directly owns 49,285 shares of the company’s stock, valued at $1,262,681.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Srinivas Akkaraju sold 1,175,713 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $29.25, for a total value of $34,389,605.25. Following the sale, the director now directly owns 5,612,896 shares in the company, valued at approximately $164,177,208. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,415,340 shares of company stock valued at $40,666,088. 19.20% of the stock is owned by corporate insiders.

Institutional Trading of Scholar Rock

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after buying an additional 514 shares during the period. Principal Financial Group Inc. acquired a new stake in Scholar Rock in the second quarter worth $98,000. Hsbc Holdings PLC bought a new stake in Scholar Rock in the 2nd quarter valued at about $100,000. Point72 DIFC Ltd acquired a new position in shares of Scholar Rock during the second quarter worth approximately $103,000. Finally, Creative Planning bought a new position in shares of Scholar Rock in the third quarter worth $115,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.